Go Pro
→ Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown” (From Paradigm Press) (Ad)tc pixel
NYSE:PEN

Penumbra Q2 2026 Earnings Report

Penumbra logo
$318.61 +0.51 (+0.16%)
Closing price 07/13/2026 03:59 PM Eastern
Extended Trading
$318.94 +0.33 (+0.10%)
As of 04:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Penumbra EPS Results

Actual EPS
N/A
Consensus EPS
$1.18
Beat/Miss
N/A
One Year Ago EPS
N/A

Penumbra Revenue Results

Actual Revenue
N/A
Expected Revenue
$389.64 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Penumbra Announcement Details

Quarter
Q2 2026
Date
8/4/2026
Time
After Market Closes
Conference Call Date
Tuesday, July 28, 2026
Conference Call Time
4:30PM ET

Conference Call Resources

Penumbra Earnings Headlines

Penumbra starts trial of clot removal device in stroke subgroup
July 8, 2026  |  yahoo.comhttps://www.yahoo.com/news/science/articles/penumbra-starts-trial-clot-removal-110000014.html
Penumbra, Inc.: First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke
July 7, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/68963726-penumbra-inc-first-patient-enrolled-in-penumbra-s-forward-study-evaluating-mechanical-thrombectomy-and-computer-assisted-vacuum-thrombectomy-for-di-008.htm
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
July 14 at 1:00 AM  |  Porter & Company (Ad)
First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke
July 7, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/first-patient-enrolled-in-penumbras-forward-study-evaluating-mechanical-thrombectomy-and-computer-assisted-vacuum-thrombectomy-for-distal-acute-ischemic-stroke-302819139.html
Penumbra Shareholders Back Directors, Auditor and Pay Policies
June 22, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/penumbra-shareholders-back-directors-auditor-and-pay-policies?utm_source=marketbeat.com&utm_medium=referral
Penumbra wins CE mark for Thunderbolt clot removal tech
June 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/penumbra-wins-ce-mark-thunderbolt-100000356.html
See More Penumbra Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Penumbra? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Penumbra and other key companies, straight to your email.

About Penumbra

Penumbra (NYSE:PEN) is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases. The company also offers embolization coil systems and flow-diversion devices for the treatment of cerebral aneurysms and vascular lesions. In its peripheral vascular line, Penumbra markets aspiration thrombectomy systems and small-vessel clot retrieval tools designed for limb salvage and treatment of pulmonary embolism.

Founded in 2004 by engineer Arani Bose, Penumbra launched its first commercial thrombectomy product in 2007 and has since expanded into new geographies and indications. The company maintains its headquarters in Alameda, California, with additional operations in Europe and Asia Pacific. Over the years, Penumbra has invested in R&D facilities and regulatory approvals to support product launches across more than 100 countries.

Under the leadership of President and Chief Executive Officer Adam Elsesser, Penumbra continues to advance its pipeline of next-generation devices, focusing on catheter design, clot visualization and real-time feedback technologies. The company collaborates with academic institutions and clinical specialists to refine procedural techniques and drive evidence generation in stroke and vascular care.

View Penumbra Profile
Earnings Tools